Braxia Scientific Corp. (BRAXF)

[JohnCM]

Dr. Roger McIntyre Elected Board Chair of Champignon Brands Inc.

Champignon Brands Inc.
Oct 05, 2020, 07:45 ET

VANCOUVER, BC, Oct. 5, 2020 /CNW/ - Dr. Roger McIntyre has been elected Chairman of the Board of Directors of Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).

A foremost international expert in depression and suicide, Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and has appointments among scientific and clinical organizations across the US and Asia.

Dr. McIntyre was appointed to the Board of Directors of Champignon on July 22, 2020 and assumed the role of CEO on May 11, 2020. He has set out a strategic direction for the business which includes a focus on "breakthrough treatments of depression" through the development of government-approved ketamine compounds and a network of treatment clinics. The Company's dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems.

The Company continues to work with the British Columbia Securities Commission to address the ongoing continuous disclosure review and is confident that the review will be resolved soon.

Bill Wilkerson, LL. D. (Hon), appointed to the Board of Directors of Champignon on May 22, 2020, has been elected Vice-Chair of the Board, bringing to the position extensive experience in business, government, and mental health.